Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аутоиммунный гастрит: от симптома к диагнозу. Клинические наблюдения
Аутоиммунный гастрит: от симптома к диагнозу. Клинические наблюдения
Ливзан М.А., Кролевец Т.С., Мозговой С.И. и др. Аутоиммунный гастрит: от симптома к диагнозу. Клинические наблюдения. Consilium Medicum. 2020; 22 (8): 78–84.
DOI: 10.26442/20751753.2020.8.200037
DOI: 110.26442/20751753.2020.8.200037
DOI: 10.26442/20751753.2020.8.200037
________________________________________________
DOI: 110.26442/20751753.2020.8.200037
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье представлено 4 клинических случая аутоиммунного гастрита. Мы рассмотрели клинические и лабораторно-инструментальные данные с целью определения ключевых показателей, характерных для данного заболевания. Обсуждены ведущие симптомы, принципы диагностики и лечения аутоиммунного гастрита. «Золотым стандартом» диагностики аутоиммунного гастрита остается эзофагогастродуоденоскопия с биопсией по OLGA-system, позволяющая определить не только стадию и степень атрофии слизистой оболочки желудка, но и наличие предраковых изменений, требующих постоянного динамического наблюдения за пациентом. Наиболее важным для постановки диагноза является обнаружение при морфологическом исследовании признаков метапластической и неметапластической атрофии желез преимущественно тела желудка наряду с гиперплазией нейроэндокринных клеток. Подтвердить диагноз также помогает серологическая диагностика для определения аутоантител класса иммуноглобулина G к париетальным клеткам и внутреннему фактору Кастла.
Ключевые слова: аутоиммунный гастрит, клинические случаи, атрофия слизистой оболочки желудка, гиперплазия нейроэндокринных клеток, антитела к париетальным клеткам.
Key words: autoimmune gastritis, clinical cases, atrophy of the gastric mucosa, hyperplasia of neuroendocrine cells, antibodies to parietal cells.
Ключевые слова: аутоиммунный гастрит, клинические случаи, атрофия слизистой оболочки желудка, гиперплазия нейроэндокринных клеток, антитела к париетальным клеткам.
________________________________________________
Key words: autoimmune gastritis, clinical cases, atrophy of the gastric mucosa, hyperplasia of neuroendocrine cells, antibodies to parietal cells.
Полный текст
Список литературы
1. Malfertheiner P, Mégraud F, O'Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV Florence Consensus Report. Gut 2012; 61: 646–64.
2. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
3. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2018; 28 (1): 55–70.
[Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterol., gepatol., koloproktol. 2018; 28 (1): 55–70 (in Russian).]
4. Мозговой С.И., Костенко М.Б., Кролевец Т.С., Ливзан М.А. Аутоиммунный гастрит в фокусе клинициста и морфолога. Фарматека. 2019; 26 (2): 121–9. DOI: 10.18565/pharmateca.2019.2.121-129
[Mozgovoi S.I., Kostenko M.B., Krolevets T.S., Livzan M.A. Autoimmunnyi gastrit v fokuse klinitsista i morfologa. Farmateka. 2019; 26 (2): 121–9. DOI: 10.18565/pharmateca.2019.2.121-129 (in Russian).]
5. Rodriguez-Castro KI, Franceschi M, Miraglia C et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed 2018; 89 (8): 100–3. DOI: 10.23750/abm.v89i8-S.7919
6. Gupta S, Li D, El Serag HB et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158 (3): 693–702. DOI: 10.1053/
j.gastro.2019.12.003
7. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40 (8): 650–8.
8. Massironi S, Cavalcoli F, Rossi RE et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol 2013; 168: 755–61.
9. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Int Med 1996; 156: 1097–100.
10. Топчий Т.Б., Минушкин О.Н. Аутоиммунный хронический гастрит – нозологическая форма или синдром? Мед. совет. 2015; 13: 38–42.
[Topchii T.B., Minushkin O.N. Autoimmunnyi khronicheskii gastrit – nozologicheskaia forma ili sindrom? Med. sovet. 2015; 13: 38–42 (in Russian).]
11. Waldron B, Cullen PT, Kumar R et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246–51.
12. Яковенко Э.П., Иванов А.Н., Илларионова Ю.В. и др. Хронический гастрит: диагностика и лечение. Фарматека. 2009; 8: 50–4.
[Iakovenko E.P., Ivanov A.N., Illarionova Iu.V. i dr. Khronicheskii gastrit: diagnostika i lechenie. Farmateka. 2009; 8: 50–4 (in Russian).]
13. Elamami AH, Elmehdwi N, Younis EZ. Pernicious Anemia Presented with Isolated Nominal Dysphasia in Type Ill Polyglandular Failure Female Patient. Cureus 2018; 10 (9): 3306. DOI: 10.7759/cureus.3306
14. Carabotti M, Lahner E, Esposito G et al. Upper gastrointestinal symptoms in autoimmune gastritis A cross-sectional study. Medicine 2017; 96 (1): 5784. DOI: 10.1097/MD.0000000000005784
15. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15 (7): 644–8.
16. Zelissen PM, Bast EJ, Croughs RJ. Associated Autoimmunity in Addison’s Disease. J Autoimmun 1995; 8 (1): 121–30.
17. Amerio P, Tracanna M, De Remigis P et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 2006; 31: 746–9.
18. Ливзан М.А., Осипенко М.Ф., Заякина Н.В., Кролевец Т.С. Многоликая проблема непереносимости глютена. Клин. медицина. 2018; 96 (2): 123–8.
[Livzan M.A., Osipenko M.F., Zaiakina N.V., Krolevets T.S. Mnogolikaia problema neperenosimosti gliutena. Klin. meditsina. 2018; 96 (2): 123–8 (in Russian).]
19. Oshima T, Okugawa T, Hori K et al. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. Intern Med 2012; 51 (10): 1211–3. DOI: 10.2169/internalmedicine.51.7077
20. Döcker D, Marx U, Braun B. Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus. Dtsch Med Wochenschr 2010; 135 (36): 1723–6. DOI: 10.1055/s-0030-1263306
21. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr 2016; 166 (13–14): 424–30. DOI: 10.1007/s10354-016-0515-5
22. Coati I, Fassan M, Farinati F et al. Autoimmune gastritis: Pathologist's viewpoint. World J Gastroenterol 2015; 21 (42): 12179–89.
23. Tozzoli R, Kodermaz G, Perosa AR et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev 2010; 10 (2): 80–3.
24. Lahner E, L Norman G, Severi C et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009; 104 (8): 2071–9. DOI: 10.1038/ajg.2009.231
25. Antico A, Tampoia M Villalta D et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol 2012; 2012: 520970. DOI: 10.1155/2012/520970
26. Bergman MP, Faller G, D'Elios MM et al. Gastric automminity. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington DC: ASM Press, 200: chapter 36.
27. D’Elios MM, J Appelmelk B, Amedei A et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10 (7): 6316–23.
28. Кононов А.В., Поморгайло Е.Г., Мозговой С.И. и др. Иммунофенотип клеток воспалительного инфильтрата как физиологическое проявление полиморфизма генов цитокинов при хроническом гастрите. Уральский мед. журн. 2019; 10 (178): 81–5.
[Kononov A.V., Pomorgailo E.G., Mozgovoi S.I. et al. Immunofenotip kletok vospalitel'nogo infil'trata kak fiziologicheskoe proiavlenie polimorfizma genov tsitokinov pri khronicheskom gastrite. Ural'skii med. zhurn. 2019; 10 (178): 81–5 (in Russian).]
29. Ливзан М.А., Кононов А.В., Мозговой С.И. Течение хронического гастрита, ассоциированного с Helicobacter pylori, в постэрадикационном периоде. Эксперимент. и клин. гастроэнтерология. 2007; 5: 116–23.
[Livzan M.A., Kononov A.V., Mozgovoi S.I. Techenie khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori, v posteradikatsionnom periode. Eksperiment. i klin. gastroenterologiia. 2007; 5: 116–23 (in Russian).]
30. Ливзан М.А. Подводные камни антихеликобактерной терапии. Терапевтический архив. 2019; 91 (8): 141–7. DOI: 10.26442/00403660.2019.08.000386
[Livzan M.A. Underwater rocks of anti-helicobacter therapy. Therapeutic Archive. 2019; 91 (8): 141–7. DOI: 10.26442/00403660.2019.08.000386 (in Russian).]
31. Chaunzwa TL, O'Shea J, Boggs NA. Hemolytic Anemia and Gastric Carcinoid in a Russian Seafarer: Highlighting the Role of Diagnostic Technologies in Modern Clinical Practice. Yale J Biol Med 2018; 91 (3): 243–6.
32. Мозговой С.И., Ливзан М.А., Кролевец Т.С., Шиманская А.Г. Нейроэндокринная опухоль как диагностический и прогностический критерий аутоиммунного гастрита. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (6): 49–59. DOI: 10.22416/1382-4376-2019-29-6-49-59
[Mozgovoi S.I., Livzan M.A., Krolevets T.S., Shimanskaia A.G. Neiroendokrinnaia opukhol' kak diagnosticheskii i prognosticheskii kriterii autoimmunnogo gastrita. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (6): 49–59. DOI: 10.22416/1382-4376-2019-29-6-49-59
(in Russian).]
33. Vannella L, Sbrozzi-Vanni A, Lahner E et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361–9. DOI: 10.1111/j.1365-2036.2011.04659.x
34. Borch K, Ahren B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242 (1): 64–73.
35. Merola E, Sbrozzi-Vanni A, Panzuto F et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95 (3): 207–13. DOI: 10.1159/000329043
36. Delle Fave G, Kwekkeboom DJ, Van Cutsem E et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012; 95: 74–87. DOI: 10.1159/000335595
37. Delle Fave G, Sundin A. Taal B et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103 (2): 119–24. DOI: 10.1159/000443168
38. Бохян В.Ю., Бельцевич Д.Г., Вашакмадзе Л.А. и др. Клинические рекомендации по лечению нейроэндокринных опухолей. Общероссийский союз общественных объединений. Ассоциация онкологов России. М., 2014.
[Bohyan V.Yu., Beltsevich D.G., Vashakmadze L.A. et al. Clinical recommendations for the treatment of neuroendocrine tumors. All-Russian Union of Public Associations. Association of Oncologists of Russia. Moscow, 2014 (in Russian).]
39. Цуканов В.В., Амельчугова О.С., Васютин А.В. и др. Тактика ведения пациентов с предраковыми изменениями в желудке. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 3: 4–8.
[Tsukanov V.V., Amel'chugova O.S., Vasiutin A.V. et al. Taktika vedeniia patsientov s predrakovymi izmeneniiami v zheludke. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 3: 4–8 (in Russian).]
40. Minalyan A, Benhammou JN, Artashesyan A et al. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol 2017; 10: 19–27.
41. Бикбавова Г.Р., Ахмедов В.А., Мухамеджанов Б.М. Методы повышения эффективности эрадикационной терапии. Рус. мед. журн. 2019; 27 (7): 6–10.
[Bikbavova G.R., Akhmedov V.A., Mukhamedzhanov B.M. Metody povysheniia effektivnosti eradikatsionnoi terapii. Rus. med. zhurn. 2019; 27 (7): 6–10 (in Russian).]
42. Li Z, Wu C, Li L et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol 2017; 23 (4): 222–8.
43. Осипенко М.Ф., Скалинская М., Ливзан М.А. Вопросы безопасности ингибиторов протонной помпы. Лечащий врач. 2016; 8: 28.
[Osipenko M.F., Skalinskaia M., Livzan M.A. Voprosy bezopasnosti ingibitorov protonnoi pompy. Lechashchii vrach. 2016; 8: 28 (in Russian).]
44. Маев И.В., Казюлин А.Н. Новые возможности профилактики рака желудка. Терапевтический архив. 2017; 89 (4): 101–7. DOI: 10.17116/terarkh2017894101-109.
[Maev I.V., Kazyulin A.N. New opportunities for the prevention of gastric cancer. Therapeutic Archive. 2017; 89 (4): 101–7 (in Russian).]. DOI: 10.17116/terarkh2017894101-109
2. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
3. Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterol., gepatol., koloproktol. 2018; 28 (1): 55–70 (in Russian).
4. Mozgovoi S.I., Kostenko M.B., Krolevets T.S., Livzan M.A. Autoimmunnyi gastrit v fokuse klinitsista i morfologa. Farmateka. 2019; 26 (2): 121–9. DOI: 10.18565/pharmateca.2019.2.121-129 (in Russian).
5. Rodriguez-Castro KI, Franceschi M, Miraglia C et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed 2018; 89 (8): 100–3. DOI: 10.23750/abm.v89i8-S.7919
6. Gupta S, Li D, El Serag HB et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158 (3): 693–702. DOI: 10.1053/
j.gastro.2019.12.003
7. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40 (8): 650–8.
8. Massironi S, Cavalcoli F, Rossi RE et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol 2013; 168: 755–61.
9. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Int Med 1996; 156: 1097–100.
10. Topchii T.B., Minushkin O.N. Autoimmunnyi khronicheskii gastrit – nozologicheskaia forma ili sindrom? Med. sovet. 2015; 13: 38–42 (in Russian).
11. Waldron B, Cullen PT, Kumar R et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246–51.
12. Iakovenko E.P., Ivanov A.N., Illarionova Iu.V. i dr. Khronicheskii gastrit: diagnostika i lechenie. Farmateka. 2009; 8: 50–4 (in Russian).
13. Elamami AH, Elmehdwi N, Younis EZ. Pernicious Anemia Presented with Isolated Nominal Dysphasia in Type Ill Polyglandular Failure Female Patient. Cureus 2018; 10 (9): 3306. DOI: 10.7759/cureus.3306
14. Carabotti M, Lahner E, Esposito G et al. Upper gastrointestinal symptoms in autoimmune gastritis A cross-sectional study. Medicine 2017; 96 (1): 5784. DOI: 10.1097/MD.0000000000005784
15. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15 (7): 644–8.
16. Zelissen PM, Bast EJ, Croughs RJ. Associated Autoimmunity in Addison’s Disease. J Autoimmun 1995; 8 (1): 121–30.
17. Amerio P, Tracanna M, De Remigis P et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 2006; 31: 746–9.
18. Livzan M.A., Osipenko M.F., Zaiakina N.V., Krolevets T.S. Mnogolikaia problema neperenosimosti gliutena. Klin. meditsina. 2018; 96 (2): 123–8 (in Russian).
19. Oshima T, Okugawa T, Hori K et al. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. Intern Med 2012; 51 (10): 1211–3. DOI:10.2169/internalmedicine.51.7077
20. Döcker D, Marx U, Braun B. Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus. Dtsch Med Wochenschr 2010; 135 (36): 1723–6. DOI: 10.1055/s-0030-1263306
21. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr 2016; 166 (13–14): 424–30. DOI: 10.1007/s10354-016-0515-5
22. Coati I, Fassan M, Farinati F et al. Autoimmune gastritis: Pathologist's viewpoint. World J Gastroenterol 2015; 21 (42): 12179–89.
23. Tozzoli R, Kodermaz G, Perosa AR et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev 2010; 10 (2): 80–3.
24. Lahner E, L Norman G, Severi C et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009; 104 (8): 2071–9. DOI: 10.1038/ajg.2009.231
25. Antico A, Tampoia M Villalta D et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol 2012; 2012: 520970. DOI: 10.1155/2012/520970
26. Bergman MP, Faller G, D'Elios MM et al. Gastric automminity. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington DC: ASM Press, 200: chapter 36.
27. D’Elios MM, J Appelmelk B, Amedei A et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10 (7): 6316–23.
28. Kononov A.V., Pomorgailo E.G., Mozgovoi S.I. et al. Immunofenotip kletok vospalitel'nogo infil'trata kak fiziologicheskoe proiavlenie polimorfizma genov tsitokinov pri khronicheskom gastrite. Ural'skii med. zhurn. 2019; 10 (178): 81–5 (in Russian).
29. Livzan M.A., Kononov A.V., Mozgovoi S.I. Techenie khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori, v posteradikatsionnom periode. Eksperiment. i klin. gastroenterologiia. 2007; 5: 116–23 (in Russian).
30. Livzan M.A. Underwater rocks of anti-helicobacter therapy. Therapeutic Archive. 2019; 91 (8): 141–7. DOI: 10.26442/00403660.2019.08.000386 (in Russian).
31. Chaunzwa TL, O'Shea J, Boggs NA. Hemolytic Anemia and Gastric Carcinoid in a Russian Seafarer: Highlighting the Role of Diagnostic Technologies in Modern Clinical Practice. Yale J Biol Med 2018; 91 (3): 243–6.
32. Mozgovoi S.I., Livzan M.A., Krolevets T.S., Shimanskaia A.G. Neiroendokrinnaia opukhol' kak diagnosticheskii i prognosticheskii kriterii autoimmunnogo gastrita. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (6): 49–59. DOI: 10.22416/1382-4376-2019-29-6-49-59 (in Russian).
33. Vannella L, Sbrozzi-Vanni A, Lahner E et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361–9. DOI: 10.1111/j.1365-2036.2011.04659.x
34. Borch K, Ahren B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242 (1): 64–73.
35. Merola E, Sbrozzi-Vanni A, Panzuto F et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95 (3): 207–13. DOI: 10.1159/000329043
36. Delle Fave G, Kwekkeboom DJ, Van Cutsem E et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012; 95: 74–87. DOI: 10.1159/000335595
37. Delle Fave G, Sundin A. Taal B et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103 (2): 119–24. DOI: 10.1159/000443168
38. Bohyan V.Yu., Beltsevich D.G., Vashakmadze L.A. et al. Clinical recommendations for the treatment of neuroendocrine tumors. All-Russian Union of Public Associations. Association of Oncologists of Russia. Moscow, 2014 (in Russian).
39. Tsukanov V.V., Amel'chugova O.S., Vasiutin A.V. et al. Taktika vedeniia patsientov s predrakovymi izmeneniiami v zheludke. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 3: 4–8 (in Russian).
40. Minalyan A, Benhammou JN, Artashesyan A et al. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol 2017; 10: 19–27.
41. Bikbavova G.R., Akhmedov V.A., Mukhamedzhanov B.M. Metody povysheniia effektivnosti eradikatsionnoi terapii. Rus. med. zhurn. 2019; 27 (7): 6–10 (in Russian).
42. Li Z, Wu C, Li L et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol 2017; 23 (4): 222–8.
43. Osipenko M.F., Skalinskaia M., Livzan M.A. Voprosy bezopasnosti ingibitorov protonnoi pompy. Lechashchii vrach. 2016; 8: 28 (in Russian).
44. Maev I.V., Kazyulin A.N. New opportunities for the prevention of gastric cancer. Therapeutic Archive. 2017; 89 (4): 101–7 (in Russian). DOI: 10.17116/terarkh2017894101-109
2. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
3. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2018; 28 (1): 55–70.
[Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterol., gepatol., koloproktol. 2018; 28 (1): 55–70 (in Russian).]
4. Мозговой С.И., Костенко М.Б., Кролевец Т.С., Ливзан М.А. Аутоиммунный гастрит в фокусе клинициста и морфолога. Фарматека. 2019; 26 (2): 121–9. DOI: 10.18565/pharmateca.2019.2.121-129
[Mozgovoi S.I., Kostenko M.B., Krolevets T.S., Livzan M.A. Autoimmunnyi gastrit v fokuse klinitsista i morfologa. Farmateka. 2019; 26 (2): 121–9. DOI: 10.18565/pharmateca.2019.2.121-129 (in Russian).]
5. Rodriguez-Castro KI, Franceschi M, Miraglia C et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed 2018; 89 (8): 100–3. DOI: 10.23750/abm.v89i8-S.7919
6. Gupta S, Li D, El Serag HB et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158 (3): 693–702. DOI: 10.1053/
j.gastro.2019.12.003
7. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40 (8): 650–8.
8. Massironi S, Cavalcoli F, Rossi RE et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol 2013; 168: 755–61.
9. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Int Med 1996; 156: 1097–100.
10. Топчий Т.Б., Минушкин О.Н. Аутоиммунный хронический гастрит – нозологическая форма или синдром? Мед. совет. 2015; 13: 38–42.
[Topchii T.B., Minushkin O.N. Autoimmunnyi khronicheskii gastrit – nozologicheskaia forma ili sindrom? Med. sovet. 2015; 13: 38–42 (in Russian).]
11. Waldron B, Cullen PT, Kumar R et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246–51.
12. Яковенко Э.П., Иванов А.Н., Илларионова Ю.В. и др. Хронический гастрит: диагностика и лечение. Фарматека. 2009; 8: 50–4.
[Iakovenko E.P., Ivanov A.N., Illarionova Iu.V. i dr. Khronicheskii gastrit: diagnostika i lechenie. Farmateka. 2009; 8: 50–4 (in Russian).]
13. Elamami AH, Elmehdwi N, Younis EZ. Pernicious Anemia Presented with Isolated Nominal Dysphasia in Type Ill Polyglandular Failure Female Patient. Cureus 2018; 10 (9): 3306. DOI: 10.7759/cureus.3306
14. Carabotti M, Lahner E, Esposito G et al. Upper gastrointestinal symptoms in autoimmune gastritis A cross-sectional study. Medicine 2017; 96 (1): 5784. DOI: 10.1097/MD.0000000000005784
15. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15 (7): 644–8.
16. Zelissen PM, Bast EJ, Croughs RJ. Associated Autoimmunity in Addison’s Disease. J Autoimmun 1995; 8 (1): 121–30.
17. Amerio P, Tracanna M, De Remigis P et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 2006; 31: 746–9.
18. Ливзан М.А., Осипенко М.Ф., Заякина Н.В., Кролевец Т.С. Многоликая проблема непереносимости глютена. Клин. медицина. 2018; 96 (2): 123–8.
[Livzan M.A., Osipenko M.F., Zaiakina N.V., Krolevets T.S. Mnogolikaia problema neperenosimosti gliutena. Klin. meditsina. 2018; 96 (2): 123–8 (in Russian).]
19. Oshima T, Okugawa T, Hori K et al. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. Intern Med 2012; 51 (10): 1211–3. DOI: 10.2169/internalmedicine.51.7077
20. Döcker D, Marx U, Braun B. Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus. Dtsch Med Wochenschr 2010; 135 (36): 1723–6. DOI: 10.1055/s-0030-1263306
21. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr 2016; 166 (13–14): 424–30. DOI: 10.1007/s10354-016-0515-5
22. Coati I, Fassan M, Farinati F et al. Autoimmune gastritis: Pathologist's viewpoint. World J Gastroenterol 2015; 21 (42): 12179–89.
23. Tozzoli R, Kodermaz G, Perosa AR et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev 2010; 10 (2): 80–3.
24. Lahner E, L Norman G, Severi C et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009; 104 (8): 2071–9. DOI: 10.1038/ajg.2009.231
25. Antico A, Tampoia M Villalta D et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol 2012; 2012: 520970. DOI: 10.1155/2012/520970
26. Bergman MP, Faller G, D'Elios MM et al. Gastric automminity. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington DC: ASM Press, 200: chapter 36.
27. D’Elios MM, J Appelmelk B, Amedei A et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10 (7): 6316–23.
28. Кононов А.В., Поморгайло Е.Г., Мозговой С.И. и др. Иммунофенотип клеток воспалительного инфильтрата как физиологическое проявление полиморфизма генов цитокинов при хроническом гастрите. Уральский мед. журн. 2019; 10 (178): 81–5.
[Kononov A.V., Pomorgailo E.G., Mozgovoi S.I. et al. Immunofenotip kletok vospalitel'nogo infil'trata kak fiziologicheskoe proiavlenie polimorfizma genov tsitokinov pri khronicheskom gastrite. Ural'skii med. zhurn. 2019; 10 (178): 81–5 (in Russian).]
29. Ливзан М.А., Кононов А.В., Мозговой С.И. Течение хронического гастрита, ассоциированного с Helicobacter pylori, в постэрадикационном периоде. Эксперимент. и клин. гастроэнтерология. 2007; 5: 116–23.
[Livzan M.A., Kononov A.V., Mozgovoi S.I. Techenie khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori, v posteradikatsionnom periode. Eksperiment. i klin. gastroenterologiia. 2007; 5: 116–23 (in Russian).]
30. Ливзан М.А. Подводные камни антихеликобактерной терапии. Терапевтический архив. 2019; 91 (8): 141–7. DOI: 10.26442/00403660.2019.08.000386
[Livzan M.A. Underwater rocks of anti-helicobacter therapy. Therapeutic Archive. 2019; 91 (8): 141–7. DOI: 10.26442/00403660.2019.08.000386 (in Russian).]
31. Chaunzwa TL, O'Shea J, Boggs NA. Hemolytic Anemia and Gastric Carcinoid in a Russian Seafarer: Highlighting the Role of Diagnostic Technologies in Modern Clinical Practice. Yale J Biol Med 2018; 91 (3): 243–6.
32. Мозговой С.И., Ливзан М.А., Кролевец Т.С., Шиманская А.Г. Нейроэндокринная опухоль как диагностический и прогностический критерий аутоиммунного гастрита. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (6): 49–59. DOI: 10.22416/1382-4376-2019-29-6-49-59
[Mozgovoi S.I., Livzan M.A., Krolevets T.S., Shimanskaia A.G. Neiroendokrinnaia opukhol' kak diagnosticheskii i prognosticheskii kriterii autoimmunnogo gastrita. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (6): 49–59. DOI: 10.22416/1382-4376-2019-29-6-49-59
(in Russian).]
33. Vannella L, Sbrozzi-Vanni A, Lahner E et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361–9. DOI: 10.1111/j.1365-2036.2011.04659.x
34. Borch K, Ahren B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242 (1): 64–73.
35. Merola E, Sbrozzi-Vanni A, Panzuto F et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95 (3): 207–13. DOI: 10.1159/000329043
36. Delle Fave G, Kwekkeboom DJ, Van Cutsem E et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012; 95: 74–87. DOI: 10.1159/000335595
37. Delle Fave G, Sundin A. Taal B et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103 (2): 119–24. DOI: 10.1159/000443168
38. Бохян В.Ю., Бельцевич Д.Г., Вашакмадзе Л.А. и др. Клинические рекомендации по лечению нейроэндокринных опухолей. Общероссийский союз общественных объединений. Ассоциация онкологов России. М., 2014.
[Bohyan V.Yu., Beltsevich D.G., Vashakmadze L.A. et al. Clinical recommendations for the treatment of neuroendocrine tumors. All-Russian Union of Public Associations. Association of Oncologists of Russia. Moscow, 2014 (in Russian).]
39. Цуканов В.В., Амельчугова О.С., Васютин А.В. и др. Тактика ведения пациентов с предраковыми изменениями в желудке. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 3: 4–8.
[Tsukanov V.V., Amel'chugova O.S., Vasiutin A.V. et al. Taktika vedeniia patsientov s predrakovymi izmeneniiami v zheludke. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 3: 4–8 (in Russian).]
40. Minalyan A, Benhammou JN, Artashesyan A et al. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol 2017; 10: 19–27.
41. Бикбавова Г.Р., Ахмедов В.А., Мухамеджанов Б.М. Методы повышения эффективности эрадикационной терапии. Рус. мед. журн. 2019; 27 (7): 6–10.
[Bikbavova G.R., Akhmedov V.A., Mukhamedzhanov B.M. Metody povysheniia effektivnosti eradikatsionnoi terapii. Rus. med. zhurn. 2019; 27 (7): 6–10 (in Russian).]
42. Li Z, Wu C, Li L et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol 2017; 23 (4): 222–8.
43. Осипенко М.Ф., Скалинская М., Ливзан М.А. Вопросы безопасности ингибиторов протонной помпы. Лечащий врач. 2016; 8: 28.
[Osipenko M.F., Skalinskaia M., Livzan M.A. Voprosy bezopasnosti ingibitorov protonnoi pompy. Lechashchii vrach. 2016; 8: 28 (in Russian).]
44. Маев И.В., Казюлин А.Н. Новые возможности профилактики рака желудка. Терапевтический архив. 2017; 89 (4): 101–7. DOI: 10.17116/terarkh2017894101-109.
[Maev I.V., Kazyulin A.N. New opportunities for the prevention of gastric cancer. Therapeutic Archive. 2017; 89 (4): 101–7 (in Russian).]. DOI: 10.17116/terarkh2017894101-109
________________________________________________
2. Sugano K, Tack J, Kuipers EJ et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–67.
3. Ivashkin V.T., Maev I.V., Lapina T.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterol., gepatol., koloproktol. 2018; 28 (1): 55–70 (in Russian).
4. Mozgovoi S.I., Kostenko M.B., Krolevets T.S., Livzan M.A. Autoimmunnyi gastrit v fokuse klinitsista i morfologa. Farmateka. 2019; 26 (2): 121–9. DOI: 10.18565/pharmateca.2019.2.121-129 (in Russian).
5. Rodriguez-Castro KI, Franceschi M, Miraglia C et al. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed 2018; 89 (8): 100–3. DOI: 10.23750/abm.v89i8-S.7919
6. Gupta S, Li D, El Serag HB et al. AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia. Gastroenterology 2020; 158 (3): 693–702. DOI: 10.1053/
j.gastro.2019.12.003
7. Rugge M, Correa P, Di Mario F et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008; 40 (8): 650–8.
8. Massironi S, Cavalcoli F, Rossi RE et al. Chronic autoimmune atrophic gastritis associated with primary hyperparathyroidism: a transversal prospective study. Eur J Endocrinol 2013; 168: 755–61.
9. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Int Med 1996; 156: 1097–100.
10. Topchii T.B., Minushkin O.N. Autoimmunnyi khronicheskii gastrit – nozologicheskaia forma ili sindrom? Med. sovet. 2015; 13: 38–42 (in Russian).
11. Waldron B, Cullen PT, Kumar R et al. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. Gut 1991; 32: 246–51.
12. Iakovenko E.P., Ivanov A.N., Illarionova Iu.V. i dr. Khronicheskii gastrit: diagnostika i lechenie. Farmateka. 2009; 8: 50–4 (in Russian).
13. Elamami AH, Elmehdwi N, Younis EZ. Pernicious Anemia Presented with Isolated Nominal Dysphasia in Type Ill Polyglandular Failure Female Patient. Cureus 2018; 10 (9): 3306. DOI: 10.7759/cureus.3306
14. Carabotti M, Lahner E, Esposito G et al. Upper gastrointestinal symptoms in autoimmune gastritis A cross-sectional study. Medicine 2017; 96 (1): 5784. DOI: 10.1097/MD.0000000000005784
15. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15 (7): 644–8.
16. Zelissen PM, Bast EJ, Croughs RJ. Associated Autoimmunity in Addison’s Disease. J Autoimmun 1995; 8 (1): 121–30.
17. Amerio P, Tracanna M, De Remigis P et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol 2006; 31: 746–9.
18. Livzan M.A., Osipenko M.F., Zaiakina N.V., Krolevets T.S. Mnogolikaia problema neperenosimosti gliutena. Klin. meditsina. 2018; 96 (2): 123–8 (in Russian).
19. Oshima T, Okugawa T, Hori K et al. Successful endoscopic submucosal dissection of gastric carcinoid in a patient with autoimmune gastritis and systemic lupus erythematosus. Intern Med 2012; 51 (10): 1211–3. DOI:10.2169/internalmedicine.51.7077
20. Döcker D, Marx U, Braun B. Gastric neuroendocrine tumors in a woman with systemic lupus erythematosus. Dtsch Med Wochenschr 2010; 135 (36): 1723–6. DOI: 10.1055/s-0030-1263306
21. Kulnigg-Dabsch S. Autoimmune gastritis. Wien Med Wochenschr 2016; 166 (13–14): 424–30. DOI: 10.1007/s10354-016-0515-5
22. Coati I, Fassan M, Farinati F et al. Autoimmune gastritis: Pathologist's viewpoint. World J Gastroenterol 2015; 21 (42): 12179–89.
23. Tozzoli R, Kodermaz G, Perosa AR et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev 2010; 10 (2): 80–3.
24. Lahner E, L Norman G, Severi C et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009; 104 (8): 2071–9. DOI: 10.1038/ajg.2009.231
25. Antico A, Tampoia M Villalta D et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol 2012; 2012: 520970. DOI: 10.1155/2012/520970
26. Bergman MP, Faller G, D'Elios MM et al. Gastric automminity. In: Mobley HLT, Mendz GL, Hazell SL, editors. Helicobacter pylori: Physiology and Genetics. Washington DC: ASM Press, 200: chapter 36.
27. D’Elios MM, J Appelmelk B, Amedei A et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004; 10 (7): 6316–23.
28. Kononov A.V., Pomorgailo E.G., Mozgovoi S.I. et al. Immunofenotip kletok vospalitel'nogo infil'trata kak fiziologicheskoe proiavlenie polimorfizma genov tsitokinov pri khronicheskom gastrite. Ural'skii med. zhurn. 2019; 10 (178): 81–5 (in Russian).
29. Livzan M.A., Kononov A.V., Mozgovoi S.I. Techenie khronicheskogo gastrita, assotsiirovannogo s Helicobacter pylori, v posteradikatsionnom periode. Eksperiment. i klin. gastroenterologiia. 2007; 5: 116–23 (in Russian).
30. Livzan M.A. Underwater rocks of anti-helicobacter therapy. Therapeutic Archive. 2019; 91 (8): 141–7. DOI: 10.26442/00403660.2019.08.000386 (in Russian).
31. Chaunzwa TL, O'Shea J, Boggs NA. Hemolytic Anemia and Gastric Carcinoid in a Russian Seafarer: Highlighting the Role of Diagnostic Technologies in Modern Clinical Practice. Yale J Biol Med 2018; 91 (3): 243–6.
32. Mozgovoi S.I., Livzan M.A., Krolevets T.S., Shimanskaia A.G. Neiroendokrinnaia opukhol' kak diagnosticheskii i prognosticheskii kriterii autoimmunnogo gastrita. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2019; 29 (6): 49–59. DOI: 10.22416/1382-4376-2019-29-6-49-59 (in Russian).
33. Vannella L, Sbrozzi-Vanni A, Lahner E et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011; 33: 1361–9. DOI: 10.1111/j.1365-2036.2011.04659.x
34. Borch K, Ahren B, Ahlman H et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242 (1): 64–73.
35. Merola E, Sbrozzi-Vanni A, Panzuto F et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012; 95 (3): 207–13. DOI: 10.1159/000329043
36. Delle Fave G, Kwekkeboom DJ, Van Cutsem E et al. ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms. Neuroendocrinology 2012; 95: 74–87. DOI: 10.1159/000335595
37. Delle Fave G, Sundin A. Taal B et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology 2016; 103 (2): 119–24. DOI: 10.1159/000443168
38. Bohyan V.Yu., Beltsevich D.G., Vashakmadze L.A. et al. Clinical recommendations for the treatment of neuroendocrine tumors. All-Russian Union of Public Associations. Association of Oncologists of Russia. Moscow, 2014 (in Russian).
39. Tsukanov V.V., Amel'chugova O.S., Vasiutin A.V. et al. Taktika vedeniia patsientov s predrakovymi izmeneniiami v zheludke. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 3: 4–8 (in Russian).
40. Minalyan A, Benhammou JN, Artashesyan A et al. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol 2017; 10: 19–27.
41. Bikbavova G.R., Akhmedov V.A., Mukhamedzhanov B.M. Metody povysheniia effektivnosti eradikatsionnoi terapii. Rus. med. zhurn. 2019; 27 (7): 6–10 (in Russian).
42. Li Z, Wu C, Li L et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol 2017; 23 (4): 222–8.
43. Osipenko M.F., Skalinskaia M., Livzan M.A. Voprosy bezopasnosti ingibitorov protonnoi pompy. Lechashchii vrach. 2016; 8: 28 (in Russian).
44. Maev I.V., Kazyulin A.N. New opportunities for the prevention of gastric cancer. Therapeutic Archive. 2017; 89 (4): 101–7 (in Russian). DOI: 10.17116/terarkh2017894101-109
Авторы
М.А. Ливзан, Т.С. Кролевец*, С.И. Мозговой, Т.В. Костоглод, А.В. Костоглод
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*mts-8-90@mail.ru
Omsk State Medical University, Omsk, Russia
*mts-8-90@mail.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*mts-8-90@mail.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*mts-8-90@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.